Inactive Instrument

La Jolla Pharmaceutical Company

Equities

LJPC

US5034596040

Biotechnology & Medical Research

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

April 06, 2015 at 09:30 pm IST

La Jolla Pharmaceutical Company announced that Dennis Mulroy will join the company as Chief Financial Officer, effective April 6, 2015. Prior to joining La Jolla, Mr. Mulroy served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc.

Latest news about La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Announces Management Changes	22/22/22	CI
La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from NASDAQ Composite Index	22/22/22	CI
La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from S&P TMI Index	22/22/22	CI
Innoviva, Inc. completed the acquisition of La Jolla Pharmaceutical Company for approximately $210 million.	22/22/22	CI
Tranche Update on La Jolla Pharmaceutical Company's Equity Buyback Plan announced on November 17, 2021.	15/22/15	CI
La Jolla Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
Sector Update: Health Care Stocks Edging Lower at Close	12/22/12	MT
Top Midday Gainers	12/22/12	MT
Sector Update: Health Care Stocks Still Little Changed	11/22/11	MT
Sector Update: Health Care	11/22/11	MT
Innoviva Agrees to Take La Jolla Pharmaceutical Private in $149 Million Acquisition Deal; Shares Rise	11/22/11	MT
La Jolla Pharmaceutical Company Equity Buyback announced on November 17, 2021, has expired, in connection with the announced merger, the stock repurchase plan was cancelled effective July 11, 2022.	11/22/11	CI
Innoviva, Inc. entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for approximately $160 million.	11/22/11	CI
La Jolla Pharmaceutical's Earnings Decline in March Quarter, Sales Increase	17/22/17	MT
Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Reports Q1 Revenue $10.4M	17/22/17	MT
Tranche Update on La Jolla Pharmaceutical Company's Equity Buyback Plan announced on November 17, 2021.	17/22/17	CI
La Jolla Pharmaceutical Company Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
North American Morning Briefing : Tech Futures -2-	13/22/13	DJ
Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q4 Revenue $75.7M	09/22/09	MT
Tranche Update on La Jolla Pharmaceutical Company's Equity Buyback Plan announced on November 17, 2021.	09/22/09	CI
La Jolla Pharmaceutical Company Reports Earnings Results for the Full Year Ended December 31, 2021	09/22/09	CI
North American Morning Briefing : Stocks to Fall, -3-	07/22/07	DJ
La Jolla Pharmaceutical Company announces an Increase in Equity Buyback.	07/22/07	CI
Insider Sell: La Jolla Pharmaceutical	02/21/02	MT
La Jolla Pharmaceutical Launches $10 Million Share Buyback Plan	17/21/17	MT

Chart La Jolla Pharmaceutical Company

Duration

Period

More charts

Company Profile

La Jolla Pharmaceutical Company is primarily engaged in the commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
REGENERON PHARMACEUTICALS, INC.	+23.21%	117B
ARGENX SE	+25.65%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.40%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B

Bio Therapeutic Drugs